OLMA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
77.5M
+15.4%
67.2M
+15.9%
58.0M
+15.8%
50.1M
+9.2%
45.9M
R&D
67.6M
+17.0%
57.8M
+17.4%
49.2M
+13.9%
43.2M
+8.2%
40.0M
SG&A
9.9M
+5.7%
9.4M
+7.3%
8.8M
+27.5%
6.9M
+15.8%
5.9M
Operating Income
-77525000
-15.4%
-67179000
-15.9%
-57986000
-15.8%
-50084000
-9.2%
-45877000
EBITDA
-77431000
-15.4%
-67077000
-15.9%
-57867000
-16.0%
-49897000
-8.9%
-45834000
Net Income
-73599000
-16.5%
-63200000
-19.0%
-53089000
-15.3%
-46061000
-9.1%
-42217000
EPS (Basic)
$-0.73
-19.7%
$-0.61
-17.3%
$-0.52
-4.0%
$-0.50
-2.0%
$-0.49
EPS (Diluted)
$-0.73
-19.7%
$-0.61
-17.3%
$-0.52
-4.0%
$-0.50
-2.0%
$-0.49
Shares (Diluted)
101.1M
-3.2%
104.5M
+1.6%
102.8M
+12.5%
91.4M
+6.6%
85.7M
Olema Oncology (OLMA) — Financials